Media
Press Releases
August 16, 2024
BITT Announced CD40 Otsuka Research and Exclusivity Agreement and New NIH Funding for TNFR2 Clinical Trial
Business Wire
August 31, 2023
BITT Announces NIH Award for Advancement of Anti-CD40 Antibody
Business Wire
August 18, 2023
BITT Announces FDA Acceptance of IND for TNFR2 Antibody
Business Wire
May 2, 2023
BITT To Present Update on CD40 Program at AAI 2023
Business Wire
December 14, 2021
BITT Announces NIH SBIR Award and New Board Member
BITT
March 17, 2021
Boston Immune Technologies and Therapeutics Raises $10M Series A Financing
Business Wire
March 9, 2021
Selexis and Boston Immune Technologies and Therapeutics (BITT) Enter Service Agreement to Advance BITT’s Lead TNFR2 Oncology Candidate
Business Wire
February 17, 2021
Boston Immune Technologies and Therapeutics and BeiGene Enter into an Exclusive Option and License Agreement to Develop Novel TNFR2 Antagonists
Business Wire
January 31, 2021
Lyfebulb and Helsinn Announce the Winners of the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Award
globenewswire.com
In The News
Beigene strikes its second overseas deal this year with BITT for TNFR2 antibodies
BioWorld | 2021-02-23
A month after multi-billion dollar Novartis deal, BeiGene follows up with ‘reverse’ deal
Endpoints News
BeiGene In-Licenses TNF-based Immunotherapy in $126 Million Agreement
Chinabiotoday.com
BioCentury Emerging Company Profile (PDF)
BioCentury | March 2018
Publications on TNF Superfamily Antagonism
TNFR2 antagonistic antibody induces the death of tumor infiltrating
CD4+ Foxp3+ regulatory T cells | Cellular Oncology
January 13, 2022
Signal Amplification in Highly Ordered Networks Is Driven by Geometry | Cells
March 2, 2021
Structures of mouse and human GITR–GITRL complexes reveal unique TNF superfamily interactions | Nature Communications
February 22, 2021
A TNFR2-hnRNPK axis promotes primary liver cancer development via activation of YAP signaling in hepatic progenitor cells | Cancer Research (aacrjournals.org)
March 24, 2020
Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL – PubMed (nih.gov)
August 5, 2019
CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches – PubMed (nih.gov)
May 28, 2018
Frontiers | TNF Receptor 2 Makes Tumor Necrosis Factor a Friend of Tumors | Immunology (frontiersin.org)
January 2, 2018
Structural principles of tumor necrosis factor superfamily signaling | Science Signaling (sciencemag.org)